Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans [A32565]. … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  2. Drug

    Sacrosidase

    go.drugbank.com/drugs/DB06760
    Approved

    Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). … Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet; therefore, sacrosidase offers a potential alternative for symptom relief.

  3. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    SP-B and SP-C. … Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as

    Products: SURVANTA ® 4 ML, SURVANTA INTRATRAKEAL SUSPANSIYON, 1 ADET
  4. Drug

    Ammonium lactate

    go.drugbank.com/drugs/DB06768
    Approved

    Ammonium lactate is the ammonium salt of lactic acid.

    Mixtures: Ultravate X, Ultravate X
  5. Drug

    Bendamustine

    go.drugbank.com/drugs/DB06769
    ApprovedInvestigational

    Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: BEN SPAL-P® 25, PURPULZ ® 180 MG/4 ML
  6. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. … [A260621] As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic IndexSynonyms: 1-HYDROXY-7.BETA.,10.BETA.-DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)
  7. Drug

    Desoxycorticosterone acetate

    go.drugbank.com/drugs/DB06780
    Approved

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. … Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: DIFLUPAD®, DİFLUNAT POMAT, 20 G
  9. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation … Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67.

    Products: GA - 67 MM-1, MON.GALYUM-67 74 MBQ/ML IV ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADET (5 ML)
  10. Drug

    Hydroxyprogesterone caproate

    go.drugbank.com/drugs/DB06789
    Approved

    Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. … FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy

    Mixtures: GRAVIDINONA 2 MLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inducers